B&C News: Endocrine Disruptors

January 11, 2017
The Top Chemical Regulatory Stories of 2016
  The attorneys, scientists, policy experts, and regulatory advisors of Bergeson & Campbell, P.C. (B&C®), The Acta Group (Acta®), and B&C® Consortia Management, L.L.C. (BCCM) endeavor year-round to keep you informed on key developments as they happen, and prepared for looming changes and deadlines, to help you maintain compliance and competitive advantage as you market your products throughout the world. As the new year begins, we offer you this look back at the top stories of 2016 (as measured by clicks, reads, and shares by readers of our blogs and e-mails), a ... read more >
September 4, 2013
EDSP Testing Consortia Forming Now to Meet EPA’s Deadline
B&C® Consortia Management, L.L.C. (BCCM) is assisting companies with forming testing consortia to fulfill regulatory requirements under the U.S. Environmental Protection Agency's (EPA) Endocrine Disruptor Screening Program (EDSP). On June 14, 2013, EPA issued the final second list of chemicals and substances for Tier 1 screening under the EDSP. Our memorandum regarding this development is provided below. EPA has indicated that it will issue test orders for the Group 2 chemicals in batches, with the first batch to be issued as early as September 2013. The EDSP has an ... read more >
April 23, 2012
Interim Guidance Sets Standards for Offers to Pay for Use of Endocrine Program Data
The April 23, 2012, issue of Bloomberg BNA Daily Environment Report quotes Lynn L. Bergeson concerning an interim guidance developed by the U.S. Environmental Protection Agency (EPA) that outlines the elements of an offer to pay for the use of inert ingredient data used to meet test orders under the Endocrine Disruptor Screening Program ... read more >
October 28, 2011
As First EDSP Test Deadline Nears, EPA Faces Host of Industry Concerns
The October 28, 2011, issue of Inside EPA quotes Bergeson & Campbell, P.C.’s October 4, 2011, memorandum regarding the U.S. Environmental Protection Agency’s final guidance on the weight-of-evidence (WoE) analysis that it will use to evaluate the results of data submitted in response to test orders issued for Tier 1 screening under the Endocrine Disruptor Screening Program ... read more >

 
BERGESON & CAMPBELL, P.C.
2200 Pennsylvania Ave, N.W. Suite 100W
Washington, D.C. 20037
(202) 557-3800 • (202) 557-3836 (fax) | lawbc.com
Contact • Twitter
 
Privacy and Terms of Use | Attorney Advertising | Trademarks
©2017 Bergeson & Campbell, P.C.
All Rights Reserved.